What Can Your Expect at the Only Dedicated Forum for Neoantigen Therapeutics?
This highly focused conference unites all the key players in the neoantigen field from Europe and US across biotech and pharma organisations. It brings together 70+ C-level executives, directors, heads and scientists focused on cancer immunotherapy, clinical & preclinical development, antigen discovery and validation, bioinformatics and regulatory considerations. All of them share the goal of developing neoantigen‑targeted therapies – making this conference a must‑attend.
Over 3 jam-packed days of content, you can expect to:
- Gain key clinical data updates
- Maximise bioinformatics and AI to improve neoantigen validation
- Understand clinical trial set up
- Analyse preclinical data to better move through the clinic
…and much more! This conference is your one-stop-shop for all things neoantigen therapy.
What Makes the International Neoantigen Summit an Unmissable Opportunity For You?
3 In-Depth Workshops
Spanning discovery to clinical development, the intimate workshops will help you overcome challenges at all points of your neoantigen therapeutic development, including:
- AI and bioinformatics to support and improve neoantigen validation
- Clinical trial setup and operational planning
- Next‑generation neoantigen development, including novel modalities
- Exploration of future combination therapies
Hear from neoantigen experts from: Khosen Bio, Transgene, Erasmus MC, and Geneos Therapeutics.
6 Brand-New Speaking Companies
Hear from these new members of the speaker faculty, who will share their clinical and preclinical data to help you better understand the direction of neoantigen therapies. Learn how to successfully progress your therapies into clinical trials.
New speaking companies include: Black Canyon Bio, CellVax Therapeutics, Echo Immune, Epitopea Ltd, Khosen Bio, and Treos Bio.
Latest Data Shared
Hear updates on techniques for neoantigen validation and target selection like immunopeptidomics and HLA profiling to better understand mutated sequences and improve targeting to help ensure highly targeted neoantigen therapies.
Hear new data from companies like: Transgene, CellVax Therapeutics, Geneos Therapeutics and more.
Explore the Full Event Guide
- Accelerating precision immunotherapy by combining bioinformatics and AI to solve neoantigen validation bottlenecks, with insights from Khosen Bio and Transgene
- Enhancing personalised cancer vaccines through real‑world clinical learnings from Evaxion’s AI‑driven neoantigen immunotherapy platform
- Advancing DNA‑encoded neoantigen vaccines to drive robust immune responses in advanced cancer patients, featuring Nykode Therapeutics
- Unlocking the dark genome to discover novel targets for affordable, multi‑valent cancer immunotherapies, with Epitopea
- Scaling personalised neoantigen peptide immunotherapy for glioblastoma by optimising development and manufacturing pathways, with YGION Biomedical
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions